New Horizons in the Treatment of Relapsed/Refractory DLBCL
New Horizons in the Treatment of Relapsed/Refractory DLBCL is organized by Horizon CME.
Course opens: 03/15/2023
Course expires: 03/15/2024
Description:
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are still characterized by poor outcomes. However, novel therapies have emerged and shown to significantly improve outcomes of these patients. This webcast will review the role of hematopoietic stem cell transplantation, new data and novel therapeutic approaches for the management of R/R DLBCL.
Learning Objectives:
• Describe the role of morphology and genetic/molecular imprints in diffuse large B-cell lymphoma (DLBCL)
• Review new treatment paradigms for relapsed/refractory (R/R) DLBCL
• Discuss the role of autologous and allogeneic hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor (CAR) T-cell in the treatment of R/R DLBCL
Additional details will be posted as soon as information is available.